Humulin M3, 100 me/ml suspension 10 ml

Humulin M3 is a DNA recombinant human insulin of medium duration of action. It is a biphasic suspension (30% Humulin Regulari 70% Humulin NPH).

The main action of the drug is regulation of glucose metabolism. In addition, it has an anabolic effect.

In muscle and other tissues (except brain) insulin causes rapid intracellular transport of glucose and amino acids and accelerates anabolism of proteins. Insulin promotes conversion of glucose into glycogen in the liver, inhibits gluconeogenesis and stimulates conversion of excess glucose into fat.

Pharmacokinetics

Humulin M3 is a medium-acting insulin drug.

The onset of action of the drug is 30 minutes after injection, the maximum effect of action is between 1 and 8.5 hours, duration of action is 14-15 hours.

Individual differences in insulin activity depend on factors such as the dose, choice of injection site, and physical activity of the patient.

Indications

Composition

1 ml of suspension for injection contains:

the active ingredient:

a mixture of human soluble insulin and 100 IU isophane insulin suspension (human soluble insulin 30% and human isophane insulin suspension 70%)

How to take, the dosage

The dose is set by the doctor individually depending on the level of glycemia.

The drug should be administered subcutaneously, intramuscular injection is possible. Intravenous injection of Humulin M3 is contraindicated!

The drug is injected subcutaneously into the shoulder, thigh, buttock or abdomen. The injection site should be rotated so that the same injection site is not used more often than about once a month.

When injecting subcutaneously, care should be taken to avoid entering a blood vessel. The injection site should not be massaged after injection. Patients should be trained in the proper use of insulin injection devices.

Regulations for preparation and administration

The Humulin M3 cartridges and vials should be rolled between the palms of the hands 10 times before use and shaken by turning 180° also 10 times to resuspend the insulin until it appears as a homogenous cloudy liquid or milk. Do not shake vigorously, as this may cause foam to form, which may interfere with proper dose delivery.

The cartridges and vials should be checked carefully. Insulin should not be used if there are flakes in it after mixing or if solid white particles are stuck to the bottom or walls of the vial, creating a frosty pattern effect.

The design of the cartridges does not allow the contents to be mixed with other insulin directly in the cartridge itself. The cartridges are not designed to be refilled.

The bottle must be drawn into an insulin syringe that has the appropriate concentration of insulin to be injected, and the correct dose of insulin must be injected as directed.

When using the cartridges, follow the manufacturer’s instructions regarding cartridge filling and needle attachment. The product should be injected according to the syringe manufacturer’s instructions.

Using the outer needle cap, immediately after injection, unscrew the needle and safely destroy it. Removing the needle immediately after injection ensures sterility and prevents leakage, air ingress and possible needle clogging. Then put the cap back on the handle.

The needles should not be reused. Needles and syringe pens should not be used by others. Cartridges and vials should be used until they are empty, at which point they should be discarded.

Interaction

The hypoglycemic effect of insulin is enhanced by MAO inhibitors, non-selective beta-adrenoblockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, phenfluramine; drugs containing ethanol.

Hypoglycemic effect of insulin is decreased by oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations, tricyclic antidepressants.

The effects of reserpine and salicylates may both weaken and enhance the effect of insulin.

Beta-adrenoblockers, clopheline, reserpine may mask the symptoms of hypoglycemia.

Ethanol, various disinfectants may decrease the biological activity of insulin.

Special Instructions

Transfer from one type of insulin to another should be done under control of blood glucose levels.

In case of insulin overdose, if the patient is conscious, glucose should be given orally; if unconscious, glucose should be given intravenously or glucagon subcutaneously, intramuscularly or intravenously.

Impact on driving and operating ability

A temporary decrease in psychomotor reactions may occur when the patient is switched to this insulin.

The initial use of insulin, change of insulin type, or significant physical or mental stress may decrease psychomotor reaction speed and ability to concentrate.

Contraindications

Hypoglycemia, insulinoma, hypersensitivity to this insulin.

Side effects

Side effects associated with the effect on carbohydrate metabolism: hypoglycemic states (pallor, increased sweating, palpitations, sleep disorders, tremors).

Allergic reactions: rare – skin rash; extremely rare – angioedema.

Local reactions: rare – hyperemia and itching at the injection site of the drug; with long-term use rarely – lipodystrophy at the injection site.

Overdose

Symptoms: hypoglycemia accompanied by lethargy, increased sweating, tachycardia, pale skin, headache, shivering, vomiting, confusion.

The precursor symptoms of hypoglycemia may change under certain conditions, such as long duration or intense control of diabetes mellitus.

Treatment: Mild states of hypoglycemia can usually be managed with oral glucose (dextrose) or sugar. Adjustment of insulin dose, diet, or physical activity may be necessary.

Correction of moderate hypoglycemia can be done with intramuscular or subcutaneous injection of glucagon, followed by oral carbohydrate intake.

Severe states of hypoglycemia accompanied by coma, seizures or neurological disorders are controlled by intramuscular or subcutaneous administration of glucagon or intravenous infusion of concentrated glucose solution (dextrose). After recovery of consciousness, the patient should be given food rich in carbohydrates, in order to avoid the recurrence of hypoglycemia.

Pregnancy use

In pregnancy and lactation, the need for insulin changes, which should be considered in order to maintain adequate metabolic control.

Insulin does not penetrate the placental barrier.